Which has better valuation and earnings, VKTX or CLYM?

Climb Bio is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Viking Therapeutics N/A N/A -$359.64M -$4.66 N/A Climb Bio N/A N/A -$59.85M -$0.83 N/A

Is VKTX or CLYM more profitable?

Climb Bio's return on equity of -31.79% beat Viking Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Viking Therapeutics N/A -94.56% -82.75% Climb Bio N/A -31.79% -30.79%

Does the media prefer VKTX or CLYM?

In the previous week, Climb Bio had 10 more articles in the media than Viking Therapeutics. MarketBeat recorded 19 mentions for Climb Bio and 9 mentions for Viking Therapeutics. Viking Therapeutics' average media sentiment score of 1.57 beat Climb Bio's score of 0.93 indicating that Viking Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Climb Bio 6 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, CLYM or TLX?

Telix Pharmaceuticals has higher revenue and earnings than Climb Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Climb Bio N/A N/A -$59.85M -$0.83 N/A Telix Pharmaceuticals $803.79M 4.77 -$7.12M N/A N/A

Is CLYM or TLX more profitable?

Telix Pharmaceuticals' return on equity of 0.00% beat Climb Bio's return on equity. Company Net Margins Return on Equity Return on Assets Climb Bio N/A -31.79% -30.79% Telix Pharmaceuticals N/A N/A N/A

Does the media favor CLYM or TLX?

In the previous week, Climb Bio had 16 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 19 mentions for Climb Bio and 3 mentions for Telix Pharmaceuticals. Climb Bio's average media sentiment score of 0.93 beat Telix Pharmaceuticals' score of 0.18 indicating that Climb Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Climb Bio 6 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Telix Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer RCUS or CLYM?

In the previous week, Climb Bio had 9 more articles in the media than Arcus Biosciences. MarketBeat recorded 19 mentions for Climb Bio and 10 mentions for Arcus Biosciences. Arcus Biosciences' average media sentiment score of 1.10 beat Climb Bio's score of 0.93 indicating that Arcus Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcus Biosciences 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Climb Bio 6 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CLYM or IOVA?

In the previous week, Iovance Biotherapeutics had 5 more articles in the media than Climb Bio. MarketBeat recorded 24 mentions for Iovance Biotherapeutics and 19 mentions for Climb Bio. Climb Bio's average media sentiment score of 0.93 beat Iovance Biotherapeutics' score of 0.58 indicating that Climb Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Climb Bio 6 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Iovance Biotherapeutics 9 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, CLYM or GRAL?

Climb Bio has higher earnings, but lower revenue than GRAIL. Climb Bio is trading at a lower price-to-earnings ratio than GRAIL, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Climb Bio N/A N/A -$59.85M -$0.83 N/A GRAIL $147.17M 24.28 -$408.35M -$9.75 N/A

Is CLYM or GRAL more profitable?

Climb Bio has a net margin of 0.00% compared to GRAIL's net margin of -236.95%. GRAIL's return on equity of -15.88% beat Climb Bio's return on equity. Company Net Margins Return on Equity Return on Assets Climb Bio N/A -31.79% -30.79% GRAIL -236.95% -15.88% -14.02%

Does the media favor CLYM or GRAL?

In the previous week, Climb Bio had 13 more articles in the media than GRAIL. MarketBeat recorded 19 mentions for Climb Bio and 6 mentions for GRAIL. GRAIL's average media sentiment score of 1.20 beat Climb Bio's score of 0.93 indicating that GRAIL is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Climb Bio 6 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GRAIL 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Climb Bio (CLYM) Competitors

$14.57 -0.49 (-3.25%)

As of 08/28/2026 04:00 PM Eastern

Compare

CLYM vs. VKTX, TLX, RCUS, IOVA, and GRAL

Should you buy Climb Bio stock or one of its competitors? Climb Bio's main competitors and comparable companies include Viking Therapeutics (VKTX), Telix Pharmaceuticals (TLX), Arcus Biosciences (RCUS), Iovance Biotherapeutics (IOVA), and GRAIL (GRAL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Climb Bio compare to Viking Therapeutics?

Viking Therapeutics (NASDAQ:VKTX) and Climb Bio (NASDAQ:CLYM) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, media sentiment, risk, analyst recommendations, institutional ownership and dividends.

Viking Therapeutics currently has a consensus price target of $96.63, suggesting a potential upside of 200.45%. Climb Bio has a consensus price target of $23.08, suggesting a potential upside of 58.43%. Given Viking Therapeutics' higher possible upside, equities analysts clearly believe Viking Therapeutics is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

Climb Bio is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.83	N/A

76.0% of Viking Therapeutics shares are held by institutional investors. Comparatively, 69.8% of Climb Bio shares are held by institutional investors. 5.3% of Viking Therapeutics shares are held by insiders. Comparatively, 2.6% of Climb Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Climb Bio's return on equity of -31.79% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-94.56%	-82.75%
Climb Bio	N/A	-31.79%	-30.79%

In the previous week, Climb Bio had 10 more articles in the media than Viking Therapeutics. MarketBeat recorded 19 mentions for Climb Bio and 9 mentions for Viking Therapeutics. Viking Therapeutics' average media sentiment score of 1.57 beat Climb Bio's score of 0.93 indicating that Viking Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Climb Bio	6 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Viking Therapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market. Comparatively, Climb Bio has a beta of 0.08, meaning that its stock price is 92% less volatile than the broader market.

Summary

Climb Bio beats Viking Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Climb Bio compare to Telix Pharmaceuticals?

Climb Bio (NASDAQ:CLYM) and Telix Pharmaceuticals (NASDAQ:TLX) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

69.8% of Climb Bio shares are owned by institutional investors. 2.6% of Climb Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Climb Bio currently has a consensus target price of $23.08, indicating a potential upside of 58.43%. Telix Pharmaceuticals has a consensus target price of $20.40, indicating a potential upside of 80.69%. Given Telix Pharmaceuticals' higher possible upside, analysts plainly believe Telix Pharmaceuticals is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00
Telix Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.86

Telix Pharmaceuticals has higher revenue and earnings than Climb Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Climb Bio	N/A	N/A	-$59.85M	-$0.83	N/A
Telix Pharmaceuticals	$803.79M	4.77	-$7.12M	N/A	N/A

Climb Bio has a beta of 0.08, suggesting that its share price is 92% less volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of -0.24, suggesting that its share price is 124% less volatile than the broader market.

In the previous week, Climb Bio had 16 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 19 mentions for Climb Bio and 3 mentions for Telix Pharmaceuticals. Climb Bio's average media sentiment score of 0.93 beat Telix Pharmaceuticals' score of 0.18 indicating that Climb Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Climb Bio	6 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Telix Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Telix Pharmaceuticals' return on equity of 0.00% beat Climb Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Climb Bio	N/A	-31.79%	-30.79%
Telix Pharmaceuticals	N/A	N/A	N/A

Summary

Climb Bio beats Telix Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does Climb Bio compare to Arcus Biosciences?

Arcus Biosciences (NYSE:RCUS) and Climb Bio (NASDAQ:CLYM) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends.

Climb Bio has lower revenue, but higher earnings than Arcus Biosciences. Climb Bio is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences	$247M	15.09	-$353M	-$3.90	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.83	N/A

92.9% of Arcus Biosciences shares are owned by institutional investors. Comparatively, 69.8% of Climb Bio shares are owned by institutional investors. 7.6% of Arcus Biosciences shares are owned by insiders. Comparatively, 2.6% of Climb Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Climb Bio had 9 more articles in the media than Arcus Biosciences. MarketBeat recorded 19 mentions for Climb Bio and 10 mentions for Arcus Biosciences. Arcus Biosciences' average media sentiment score of 1.10 beat Climb Bio's score of 0.93 indicating that Arcus Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcus Biosciences	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Climb Bio	6 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arcus Biosciences currently has a consensus price target of $37.80, suggesting a potential upside of 29.14%. Climb Bio has a consensus price target of $23.08, suggesting a potential upside of 58.43%. Given Climb Bio's stronger consensus rating and higher possible upside, analysts clearly believe Climb Bio is more favorable than Arcus Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

Arcus Biosciences has a beta of 0.8, suggesting that its share price is 20% less volatile than the broader market. Comparatively, Climb Bio has a beta of 0.08, suggesting that its share price is 92% less volatile than the broader market.

Climb Bio has a net margin of 0.00% compared to Arcus Biosciences' net margin of -393.16%. Climb Bio's return on equity of -31.79% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences	-393.16%	-89.54%	-45.61%
Climb Bio	N/A	-31.79%	-30.79%

Summary

Climb Bio beats Arcus Biosciences on 10 of the 16 factors compared between the two stocks.

How does Climb Bio compare to Iovance Biotherapeutics?

Climb Bio (NASDAQ:CLYM) and Iovance Biotherapeutics (NASDAQ:IOVA) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

69.8% of Climb Bio shares are owned by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are owned by institutional investors. 2.6% of Climb Bio shares are owned by company insiders. Comparatively, 7.8% of Iovance Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Climb Bio has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -89.11%. Climb Bio's return on equity of -31.79% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Climb Bio	N/A	-31.79%	-30.79%
Iovance Biotherapeutics	-89.11%	-40.51%	-31.65%

Climb Bio presently has a consensus target price of $23.08, suggesting a potential upside of 58.43%. Iovance Biotherapeutics has a consensus target price of $8.89, suggesting a potential upside of 10.97%. Given Climb Bio's stronger consensus rating and higher possible upside, research analysts clearly believe Climb Bio is more favorable than Iovance Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00
Iovance Biotherapeutics	2 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.45

Climb Bio has higher earnings, but lower revenue than Iovance Biotherapeutics. Climb Bio is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Climb Bio	N/A	N/A	-$59.85M	-$0.83	N/A
Iovance Biotherapeutics	$263.50M	13.77	-$390.98M	-$0.73	N/A

Climb Bio has a beta of 0.08, meaning that its share price is 92% less volatile than the broader market. Comparatively, Iovance Biotherapeutics has a beta of 0.71, meaning that its share price is 29% less volatile than the broader market.

In the previous week, Iovance Biotherapeutics had 5 more articles in the media than Climb Bio. MarketBeat recorded 24 mentions for Iovance Biotherapeutics and 19 mentions for Climb Bio. Climb Bio's average media sentiment score of 0.93 beat Iovance Biotherapeutics' score of 0.58 indicating that Climb Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Climb Bio	6 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Iovance Biotherapeutics	9 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Climb Bio beats Iovance Biotherapeutics on 9 of the 16 factors compared between the two stocks.

How does Climb Bio compare to GRAIL?

Climb Bio (NASDAQ:CLYM) and GRAIL (NASDAQ:GRAL) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings.

Climb Bio has higher earnings, but lower revenue than GRAIL. Climb Bio is trading at a lower price-to-earnings ratio than GRAIL, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Climb Bio	N/A	N/A	-$59.85M	-$0.83	N/A
GRAIL	$147.17M	24.28	-$408.35M	-$9.75	N/A

Climb Bio presently has a consensus price target of $23.08, indicating a potential upside of 58.43%. GRAIL has a consensus price target of $67.78, indicating a potential downside of 15.28%. Given Climb Bio's stronger consensus rating and higher probable upside, analysts plainly believe Climb Bio is more favorable than GRAIL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00
GRAIL	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30

Climb Bio has a net margin of 0.00% compared to GRAIL's net margin of -236.95%. GRAIL's return on equity of -15.88% beat Climb Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Climb Bio	N/A	-31.79%	-30.79%
GRAIL	-236.95%	-15.88%	-14.02%

Climb Bio has a beta of 0.08, indicating that its share price is 92% less volatile than the broader market. Comparatively, GRAIL has a beta of 3.24, indicating that its share price is 224% more volatile than the broader market.

69.8% of Climb Bio shares are held by institutional investors. 2.6% of Climb Bio shares are held by insiders. Comparatively, 1.8% of GRAIL shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Climb Bio had 13 more articles in the media than GRAIL. MarketBeat recorded 19 mentions for Climb Bio and 6 mentions for GRAIL. GRAIL's average media sentiment score of 1.20 beat Climb Bio's score of 0.93 indicating that GRAIL is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Climb Bio	6 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GRAIL	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Climb Bio beats GRAIL on 10 of the 16 factors compared between the two stocks.

Get Climb Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLYM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLYM vs. The Competition

Export

Metric	Climb Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$836.84M	$3.94B	$7.21B	$12.91B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-17.55	11.62	273.16	25.45
Price / Sales	N/A	1,359.72	625.22	90.88
Price / Cash	N/A	106.39	76.74	53.00
Price / Book	3.49	16.53	12.98	6.14
Net Income	-$59.85M	-$22.80M	$3.48B	$348.86M
7 Day Performance	-15.68%	-0.31%	0.13%	-0.80%
1 Month Performance	19.72%	9.80%	7.08%	4.13%
1 Year Performance	553.36%	55.66%	24.67%	15.17%

Climb Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLYM Climb Bio	2.6204 of 5 stars	$14.57 -3.3%	$23.08 +58.4%	+553.4%	$836.84M	N/A	N/A	9	Options Volume Analyst Revision
VKTX Viking Therapeutics	3.0483 of 5 stars	$33.89 -1.4%	$96.63 +185.1%	+18.9%	$3.95B	N/A	N/A	20	Positive News
TLX Telix Pharmaceuticals	3.7999 of 5 stars	$11.33 -8.8%	$20.40 +80.1%	+18.2%	$3.85B	$803.79M	N/A	1,184	Gap Down
RCUS Arcus Biosciences	3.1706 of 5 stars	$30.14 +2.1%	$37.80 +25.4%	+176.3%	$3.84B	$117M	N/A	500
IOVA Iovance Biotherapeutics	1.9718 of 5 stars	$8.29 -7.8%	$8.75 +5.5%	+259.2%	$3.76B	$263.50M	N/A	500	Trending News Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLYM) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Climb Bio (CLYM) Competitors

CLYM vs. VKTX, TLX, RCUS, IOVA, and GRAL

How does Climb Bio compare to Viking Therapeutics?

Summary

How does Climb Bio compare to Telix Pharmaceuticals?

Summary

How does Climb Bio compare to Arcus Biosciences?

Summary

How does Climb Bio compare to Iovance Biotherapeutics?

Summary

How does Climb Bio compare to GRAIL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLYM vs. The Competition

Climb Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Climb Bio (CLYM) Competitors

CLYM vs. VKTX, TLX, RCUS, IOVA, and GRAL

How does Climb Bio compare to Viking Therapeutics?

Do analysts prefer VKTX or CLYM?

Which has better valuation and earnings, VKTX or CLYM?

Do institutionals & insiders hold more shares of VKTX or CLYM?

Is VKTX or CLYM more profitable?

Does the media prefer VKTX or CLYM?

Which has more risk and volatility, VKTX or CLYM?

Summary

How does Climb Bio compare to Telix Pharmaceuticals?

Do insiders & institutionals believe in CLYM or TLX?

Do analysts recommend CLYM or TLX?

Which has better valuation & earnings, CLYM or TLX?

Which has more risk & volatility, CLYM or TLX?

Does the media favor CLYM or TLX?

Is CLYM or TLX more profitable?

Summary

How does Climb Bio compare to Arcus Biosciences?

Which has preferable valuation and earnings, RCUS or CLYM?

Do insiders and institutionals hold more shares of RCUS or CLYM?

Does the media prefer RCUS or CLYM?

Do analysts rate RCUS or CLYM?

Which has more risk & volatility, RCUS or CLYM?

Is RCUS or CLYM more profitable?

Summary

How does Climb Bio compare to Iovance Biotherapeutics?

Do institutionals & insiders hold more shares of CLYM or IOVA?

Is CLYM or IOVA more profitable?

Do analysts recommend CLYM or IOVA?

Which has preferable earnings and valuation, CLYM or IOVA?

Which has more risk & volatility, CLYM or IOVA?

Does the media favor CLYM or IOVA?

Summary

How does Climb Bio compare to GRAIL?

Which has stronger earnings & valuation, CLYM or GRAL?

Do analysts prefer CLYM or GRAL?

Is CLYM or GRAL more profitable?

Which has more volatility & risk, CLYM or GRAL?

Do institutionals & insiders believe in CLYM or GRAL?

Does the media favor CLYM or GRAL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLYM vs. The Competition

Climb Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools